Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

BackgroundChemotherapy resistance remains a major obstacle in the treatment of women with ovarian cancer. Establishing predictive markers of chemoresponse would help to individualize therapy and improve survival of ovarian cancer patients. Chemotherapy resistance in ovarian cancer has been studied thoroughly and several non-overlapping single genes, gene profiles and copy number alterations have been suggested as potential markers. The objective of this study was to explore genetic alterations behind chemotherapy resistance in ovarian cancer with the ultimate aim to find potential predictive markers.MethodsTo create the best opportunities for identifying genetic alterations of importance for resistance, we selected a homogenous tumor material concerning histology, stage and chemotherapy. Using high-resolution whole genome array comparative genomic hybridization (CGH), we analyzed the tumor genomes of 40 fresh-frozen stage III ovarian serous carcinomas, all uniformly treated with combination therapy paclitaxel/carboplatin. Fisher's exact test was used to identify significant differences. Subsequently, we examined four genes in the significant regions (EVI1, MDS1, SH3GL2, SH3KBP1) plus the ABCB1 gene with quantitative real-time polymerase chain reaction (QPCR) to evaluate the impact of DNA alterations on the transcriptional level.ResultsWe identified gain in 3q26.2, and losses in 6q11.2-12, 9p22.3, 9p22.2-22.1, 9p22.1-21.3, Xp22.2-22.12, Xp22.11-11.3, and Xp11.23-11.1 to be significantly associated with chemotherapy resistance. In the gene expression analysis, EVI1 expression differed between samples with gain versus without gain, exhibiting higher expression in the gain group.ConclusionIn conclusion, we detected specific genetic alterations associated with resistance, of which some might be potential predictive markers of chemotherapy resistance in advanced ovarian serous carcinomas. Thus, further studies are required to validate these findings in an independent ovarian tumor series.

[1]  Y. Wan,et al.  Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. , 2008, Cancer letters.

[2]  I. Nagata,et al.  Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Ian H. Witten,et al.  Data mining in bioinformatics using Weka , 2004, Bioinform..

[4]  J. Staaf,et al.  High-Resolution Genomic Profiling of Carboplatin Resistance in Early-Stage Epithelial Ovarian Carcinoma , 2009, Cytogenetic and Genome Research.

[5]  J. Inazawa,et al.  TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Eastman,et al.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. , 1990, Biochemical pharmacology.

[7]  J. Rowley,et al.  Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Nogales,et al.  Structure of the alpha beta tubulin dimer by electron crystallography. , 1998, Nature.

[9]  Jane Fridlyand,et al.  Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .

[10]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[11]  R. Burger,et al.  Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. , 2005, Cancer research.

[12]  S. Minkin,et al.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.

[13]  Hanna Göransson,et al.  Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.

[14]  Johan Staaf,et al.  High‐resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization , 2007, Genes, chromosomes & cancer.

[15]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.

[16]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Q. Zhan,et al.  Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma , 2008, Genes, chromosomes & cancer.

[18]  A. Tsalenko,et al.  High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin‐resistant ovarian cancer cells , 2007, Genes, chromosomes & cancer.

[19]  E. Gehan.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[20]  K. Helou,et al.  Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. , 2005, Cancer genetics and cytogenetics.

[21]  E. Partridge,et al.  Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.

[22]  S. Knuutila,et al.  Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells , 1997, Genes, chromosomes & cancer.

[23]  Jaakko Astola,et al.  CGH-Plotter: MATLAB toolbox for CGH-data analysis , 2003, Bioinform..

[24]  Wen-Lin Kuo,et al.  Specific keynote: genome copy number abnormalities in ovarian cancer. , 2003, Gynecologic oncology.

[25]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[26]  Johan Staaf,et al.  Normalization of array-CGH data: influence of copy number imbalances , 2007, BMC Genomics.

[27]  György Horvath,et al.  Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. , 2006, European journal of cancer.

[28]  K. Helou,et al.  Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage , 2004, Genes, chromosomes & cancer.

[29]  I. Bairati,et al.  Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas , 2008, Modern Pathology.

[30]  K. Kitada,et al.  The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. , 2008, Cancer genetics and cytogenetics.

[31]  D. Alberts,et al.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers. , 1996, British Journal of Cancer.

[32]  Y. Luqmani.  Mechanisms of Drug Resistance in Cancer Chemotherapy , 2005, Medical Principles and Practice.

[33]  D. Juric,et al.  Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell lines , 2006, Genes, chromosomes & cancer.

[34]  J. Ihle,et al.  Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. , 1990, Oncogene.

[35]  E. Thompson,et al.  Evi1 is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via PI3K/AKT , 2006, Oncogene.

[36]  M. Botta,et al.  Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes , 2007, ChemMedChem.

[37]  S. Gruvberger,et al.  BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data , 2002, Genome Biology.

[38]  G. Samimi,et al.  The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. , 2003, Molecular pharmacology.

[39]  G. Nucifora,et al.  EVI1 and hematopoietic disorders: history and perspectives. , 2006, Gene.

[40]  I. Wistuba,et al.  Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. , 2000, Cancer genetics and cytogenetics.

[41]  Jae Hoon Kim,et al.  Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease , 2007, Genes, chromosomes & cancer.

[42]  I. Dikic,et al.  Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.

[43]  S. Kaye.  Reversal of drug resistance in ovarian cancer: where do we go from here? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Goto,et al.  Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. , 2001, Human cell.

[45]  S. Johnson,et al.  Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.

[46]  K. Kitada,et al.  Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. , 2007, Cancer genetics and cytogenetics.

[47]  Wen-Lin Kuo,et al.  Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. , 2007, Cancer research.

[48]  V. Torri,et al.  Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. , 1997, Gynecologic oncology.

[49]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[50]  Shu-Kay Ng,et al.  Relationship of XIST expression and responses of ovarian cancer to chemotherapy. , 2002, Molecular cancer therapeutics.